A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418 Journal Article


Authors: Jhingran, A; Winter, K; Portelance, L; Miller, B.; Salehpour, M.; Gaur, R; Souhami, L.; Small, W., Jr; Berk, L.; Gaffney, D
Article Title: A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418
Abstract: PURPOSE: To determine the feasibility of pelvic intensity modulated radiation therapy (IMRT) for patients with endometrial cancer in a multi-institutional setting and to determine whether this treatment is associated with fewer short-term bowel adverse events than standard radiation therapy. METHODS: Patients with adenocarcinoma of the endometrium treated with pelvic radiation therapy alone were eligible. Guidelines for target definition and delineation, dose prescription, and dose-volume constraints for the targets and critical normal structures were detailed in the study protocol and a web-based atlas. RESULTS: Fifty-eight patients were accrued by 25 institutions; 43 were eligible for analysis. Forty-two patients (98%) had an acceptable IMRT plan; 1 had an unacceptable variation from the prescribed dose to the nodal planning target volume. The proportions of cases in which doses to critical normal structures exceeded protocol criteria were as follows: bladder, 67%; rectum, 76%; bowel, 17%; and femoral heads, 33%. Twelve patients (28%) developed grade >/=2 short-term bowel adverse events. CONCLUSIONS: Pelvic IMRT for endometrial cancer is feasible across multiple institutions with use of a detailed protocol and centralized quality assurance (QA). For future trials, contouring of vaginal and nodal tissue will need continued monitoring with good QA and better definitions will be needed for organs at risk.
Journal Title: International journal of radiation oncology, biology, physics
Volume: 84
Issue: 1
ISSN: 1879-355X; 0360-3016
Publisher: Elsevier Inc  
Journal Place: United States
Date Published: 2012
Start Page: e23
End Page: 8
Language: eng
DOI/URL:
Notes: CI: Copyright (c) 2012; GR: U10 CA21661/CA/NCI NIH HHS/United States; GR: U10 CA3742/CA/NCI NIH HHS/United States; GR: U24 CA81647/CA/NCI NIH HHS/United States; JID: 7603616; 2011/09/12 [received]; 2012/02/07 [revised]; 2012/02/20 [accepted]; 2012/04/28 [aheadofprint]; ppublish